Integrative evaluation of primary and metastatic lesion spectrum to guide anti-PD-L1 therapy of non-small cell lung cancer: results from two randomized studies. - Ma SC; Tang XR; Long LL; Bai X; Zhou JG; Duan ZJ; Wang J; Fu QJ; Zhu HB; Guo XJ; Zhang YP; Guo ZQ; et al. (Oncoimmunology, 2021)